USA: A 27-week study published in The Lancet Neurology has revealed that tavapadon, a selective dopamine D1/D5 receptor agonist, produced significant and clinically meaningful improvements in motor symptoms among patients with Parkinson’s disease. The study evaluated the safety, tolerability, and efficacy of flexible-dose tavapadon in adults with early-stage Parkinson's disease. Parkinson's disease is commonly treated with dopaminergic therapies, but existing options have important drawbacks. Researchers evaluated tavapadon in the phase 3, randomized, double-blind, placebo-controlled TEMPO-2 trial involving adults aged 40–80 years with early-stage Parkinson's disease across 75 centers in 13 countries. Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): A phase 3, randomised, placebo-controlled, double-blind trial.